TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8758169
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.06% bupivacaine with fentanyl 4 micrograms.ml‐1 (group F)
Study: 8758169
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.06% bupivacaine with pethidine 1.5 mg.ml‐1 (group P)
Study: 8758169
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion rates in both groups
Study: 25175921
Drug: Prehospital ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehospital ticagrelor administration
Study: 25175921
Drug: In-hospital ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-hospital ticagrelor administration
Study: 19800815
Drug: Amiodarone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (150 mg in 10 mL of normal saline)
Study: 19809326
Drug: Amiodarone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (150 mg)
Study: 17922444
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents for hemoglobin normalization
Study: 17922444
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents for calcium-phosphate metabolism (phosphate binders not containing calcium and aluminum, vitamin D analogs with lower calcemic activity, calcimimetics)
Study: 16392704
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extracts/powder containing 544 mg polyphenols (456 mg catechins) daily for 2 months
Study: 12480476
Drug: Visual context
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visual context supporting the preferred interpretation of the ambiguous phrase (e.g., 'Put the apple on the towel in the box')
Study: 2523647
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus Isradipine (1.25 mg twice daily)
Study: 2523647
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus Hydrochlorothiazide (12.5 mg per day)
Study: 326384
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy for 12 monthly cycles
Study: 23197840
Drug: Concurrent somatic
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent somatic depressive symptoms
Study: 23197840
Drug: Concurrent affective
Normalized name: Solutions affecting the electrolyte balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent affective depressive symptoms
Study: 23197840
Drug: Concurrent anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent anxiety symptoms
Study: 14505443
Drug: Routine hospice
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine hospice services and clinical music therapy
Study: 10866713
Drug: Ephedrine (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (0.08 mg x kg‐1 intravenously)
Study: 10866713
Drug: Etilefrine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine (0.02 mg x kg‐1 intravenously)
Study: 9109708
Drug: Narrow-band red
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band red light phototherapy at 660 nm for 4.4 minutes three times a day for 14 days (total dose 6 joules per day)
Study: 1470889
Drug: Taurolin (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolin (topical application)
Study: 1470889
Drug: Chlortetracycline (Aureomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortetracycline (Aureomycin, topical application)
Study: 2863090
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray
Study: 22606044
Drug: Donepezil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil plus natural hirudin (3 g/day)
Study: 22606044
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for the first 4 weeks and 10 mg/day thereafter)
Study: 20537124
Drug: Internet group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet group (n = 101) that monitored asthma control weekly with the ACQ on the Internet and adjusted treatment using a self‐management algorithm supervised by an asthma nurse specialist
Study: 12136399
Drug: 5-methyltetrahydrofolate (5-MTHF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-methyltetrahydrofolate (5-MTHF, 1 microg/100 ml FAV/min)
Study: 10654798
Drug: 111In‐labelled resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 111In‐labelled resin (150‐300 microm) administered in the morning (0800h)
Study: 10654798
Drug: 99mTc‐labelled non‐disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐labelled non‐disintegrating capsule (22 x 8 mm) administered in the morning (0800h)
Study: 10654798
Drug: 111In‐labelled resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 111In‐labelled resin (150‐300 microm) administered in the evening (1700h)
Study: 10654798
Drug: 99mTc‐labelled non‐disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐labelled non‐disintegrating capsule (22 x 8 mm) administered in the evening (1700h)
Study: 2194270
Drug: IVIG (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (1 g/d)
Study: 7008062
Drug: Prostacyclin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin infusion at a dosage of 8 ng/kg/min
Study: 30601837
Drug: Reappraisal (twice)
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reappraisal (twice)
Study: 30601837
Drug: Rumination (twice)
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rumination (twice)
Study: 29602751
Drug: Ivermectin 600
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 600 μg/kg per day for 3 days
Study: 29602751
Drug: Ivermectin 300
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 300 μg/kg per day for 3 days
Study: 26294205
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (PFMT) daily program from 20 to 36 weeks' gestation
Study: 16841630
Drug: Olanzapine-fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine-fluoxetine combination
Study: 10688033
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin (HCG) treatment
Study: 9095326
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen (metoclopramide, dexamethasone, lorazepam, orphenadrine)
Study: 8459263
Drug: Chemoprophylaxis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprophylaxis and immunoprophylaxis (thymostimulin 70 mg i.m. per day for 7 days + 2 g cefotetan at induction)
Study: 8459263
Drug: Chemoprophylaxis only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprophylaxis only (2 g cefotetan at induction)
Study: 3516016
Drug: Intravenous lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lidocaine, 3 mg/kg, followed by an infusion of 0.05 mg X kg‐1 X min‐1
Study: 3516016
Drug: Intravenous lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lidocaine, 3 mg/kg
Study: 28899879
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake (2.4 g/kg/d)
Study: 28899879
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein intake (1.2 g/kg/d)
Study: 27378474
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg/day
Study: 12766602
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day protocol (morning injection and afternoon surgery)
Study: 12766602
Drug: 2 day
Normalized name: Sterapred 12 DAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 day protocol (day before afternoon injection and morning surgery)
Study: 12766602
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of 99mTc‐rhenium sulphide colloid
Study: 10487404
Drug: Anethole trithione
Normalized name: anethole trithione
DrugBank: Anethole trithione (DB13853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anethole trithione (AT) - 6 tablets per day
Study: 7588175
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of antidepressants
Study: 3407609
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg beta-carotene
Study: 3407609
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg beta-carotene (daily dosing)
Study: 3407609
Drug: Pharmacological doses
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological doses of beta-carotene (45 and 90 mg)
Study: 764997
Drug: Trivalent vaccine
Normalized name: Fluzone 2024-2025 trivalent vaccine Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent vaccine (measles, mumps, rubella)
Study: 28289865
Drug: Pimasertib tablet
Normalized name: Capivasertib
DrugBank: Pimasertib (DB14904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimasertib tablet (3 × 20 mg, PO QD)
Study: 28289865
Drug: Pimasertib capsule
Normalized name: Capivasertib
DrugBank: Pimasertib (DB14904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimasertib capsule (2 × 30 mg, PO QD)
Study: 23478893
Drug: Full-dose protocol
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose protocol (group A)
Study: 23478893
Drug: Half-dose protocol
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose protocol (group B)
Study: 21320171
Drug: Platform switching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform switching with a 3.3 mm diameter abutment on test implants
Study: 21320171
Drug: Control implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implant with a straight 4 mm diameter abutment
Study: 21320171
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of test and control implants
Study: 21320171
Drug: Bacterial contamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial contamination in implants
Study: 8041168
Drug: Surgical intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical intervention and antibiotics
Study: 162669
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren) 25 mg t.i.d.
Study: 30889044
Drug: Intra-Aortic Balloon
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-Aortic Balloon Pump (IABP) therapy
Study: 27502326
Drug: Fimasartan/Amlodipine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan/Amlodipine 60 mg/10 mg
Study: 15634953
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PV)
Study: 463800
Drug: Concurrent energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent energy provision
Study: 31813633
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid 25 mg
Study: 26357703
Drug: Enamel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix derivative (EMD) 0.1 mL topically applied to soft tissues surrounding implants
Study: 26357703
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment applied)
Study: 23351812
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone for 6 weeks
Study: 23351812
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w injection for 3 months
Study: 23351812
Drug: Safety of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety of immunomodulatory treatment
Study: 23351812
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral prednisolone
Study: 23351812
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Mycobacterium w injection
Study: 19247497
Drug: Intravenous opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioid analgesia and general anesthesia (IV group)
Study: 17298428
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate 0.1% ointment once daily
Study: 17298428
Drug: Tacrolimus 0.03%
Normalized name: TACROLIMUS 0.03% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.03% ointment twice daily
Study: 17298428
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate 0.1% ointment
Study: 2996332
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 to 20 mg bid)
Study: 2996332
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 to 50 mg bid)
Study: 2996332
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Enalapril + Hydrochlorothiazide)
Study: 24176534
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (MED)
Study: 19835829
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of MF59 with various antigen levels
Study: 19835829
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of vaccine
Study: 9821828
Drug: Echinacea treatments
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea treatments
Study: 17642235
Drug: Tocilizumab (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (humanized anti-human IL-6 receptor antibody)
Study: 15080023
Drug: Barnidipine hydrochloride
Normalized name: barnidipine hydrochloride
DrugBank: Barnidipine (DB09227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine hydrochloride at a titrated dose of 10-15 mg once daily for 8 weeks
Study: 11262334
Drug: Dietetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietetic therapy
Study: 11262334
Drug: HMG-CoA-reductase inhibitors
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA-reductase inhibitors management
Study: 8042733
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine 2 mg in 40 ml of normal saline
Study: 8042733
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 2 mg in 1 ml of normal saline
Study: 1429339
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) consisting of topical polymyxin E, tobramycin, and amphotericin B administered throughout the unit stay together with parenteral ceftazidime for the first three days.
Study: 31552815
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori IgG antibody sero-prevalence among Arabs
Study: 31552815
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori IgG antibody sero-prevalence among Jews
Study: 31552815
Drug: CagA IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: CagA IgG antibody sero-positivity among H. pylori positives in Arabs
Study: 31552815
Drug: CagA IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: CagA IgG antibody sero-positivity among H. pylori positives in Jews
Study: 24943857
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg (2 mL) dexketoprofen
Study: 24943857
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL normal saline (control)
Study: 11391126
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg entacapone
Study: 11391126
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg entacapone
Study: 9679843
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (50 or 100 microg twice daily)
Study: 2512765
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 mcg
Study: 24809448
Drug: Levodopa/Carbidopa treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/Carbidopa treatment for patients with low DβH activity genotypes (CT/TT)
Study: 24809448
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for patients with low DβH activity genotypes (CT/TT)
Study: 24809448
Drug: Levodopa/Carbidopa treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/Carbidopa treatment for patients with normal DβH activity genotype (CC)
Study: 19020325
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy
Study: 15821274
Drug: Pramlintide mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide mixed with short-acting insulin
Study: 15821274
Drug: Pramlintide mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide mixed with long-acting insulin
Study: 15821274
Drug: Separate injections
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injections of pramlintide and insulin
Study: 15821274
Drug: Pramlintide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide and insulin mixtures
Study: 10391163
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 10 ml through a subcutaneous catheter
Study: 10391163
Drug: Dipyrone 500
Normalized name: dipyrone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 500 mg orally
Study: 8871418
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy plus family management (CBT + FAM)
Study: 8871418
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effectiveness
Study: 6207648
Drug: Ethambutol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethambutol (20 mg/kg bodyweight/day) with streptomycin and isoniazid (SHE)
Study: 11863299
Drug: Formulation 1
Normalized name: Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation 10 MCG per 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 1 (150 mg)
Study: 11863299
Drug: Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 2 (150 mg)
Study: 25456363
Drug: Unfav-dose-dense group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfav-dose-dense group
Study: 23064478
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (onabotulinumtoxinA; 140-200 units) injections into the pectoralis major with or without injections to the teres major
Study: 23064478
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (onabotulinumtoxinA; 140-200 units) injections
Study: 20103445
Drug: Continuous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regimen of ethinylestradiol (30 mcg) and drospirenone (3 mg) for 168 days
Study: 20103445
Drug: Traditional cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional cyclic regimen of ethinylestradiol (30 mcg) and drospirenone (3 mg) for six 28-day cycles with a 7-day hormone-free interval
Study: 15694572
Drug: Single course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single course of hylan G-F 20
Study: 15694572
Drug: Repeat course
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat course of hylan G-F 20
Study: 15694572
Drug: Appropriate care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate care without hylan G-F 20
Study: 12706743
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of diethyl carbamazine citrate (DEC)
Study: 12706743
Drug: 14 day
Normalized name: Ponvory 14 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day treatment with diethyl carbamazine citrate (DEC)
Study: 10361567
Drug: Version M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Version M (mainstream drug - Metoprolol)
Study: 10361567
Drug: Version V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Version V (unconventional drug - beef spleen cell extract)